In severe case of COVID-19… Vitamin C is ineffective or harmful VS Hyperlipidemia drug ‘Stein’, 96% treatment effect
Entered 2023.10.27 13:10 Views 1,108 Entered 2023.10.27 13:10 Modified 2023.10.27 16:03 Views 1,108
It was found that even very high concentrations of vitamin C were not helpful in treating COVID-19. On the contrary, it can be harmful. On the other hand, hyperlipidemia drugs that lower cholesterol levels have high therapeutic effects. [사진=게티이미지뱅크]High doses of vitamin C or stein-type hyperlipidemia drugs were administered to critically ill patients hospitalized with COVID-19. However, two international studies have shown that for these patients, vitamin C has little effect or may actually be harmful, while hyperlipidemia drugs are of great help in treatment.
According to international research results from Imperial College London (ICL) in the UK, COVID-19 patients who took simvastatin, a hyperlipidemic drug that lowers cholesterol levels, had good results, including a 92% improvement in survival rate after 3 months and a shortening of the patient’s intensive care unit treatment period. The probability of paying was found to be 96%. This study is part of an ongoing specific clinical trial (EMAP-CAP). More than 2,600 seriously ill COVID-19 patients from 141 hospitals in 13 countries around the world participated. It is the world’s largest in this field.
Professor Danny Macauley (Biomedical Science) of Queen’s University, UK, a member of the research team, said, “It is encouraging that simvastatin treatment is likely to improve the outcomes of severe COVID-19 patients. “This equates to saving one life for every 33 patients treated with simvastatin, which is inexpensive and widely used.” He is the lead author of a clinical trial study on simvastatin treatment.
The results of this study (Simvastatin in Critically Ill Patients with Covid-19) were published in the New England Journal of Medicine.
Intravenous injection of high-dose vitamin C, 100 times higher than that of supplements, is not effective and may actually be harmful.
A separate international study found that high-dose intravenous vitamin C for hospitalized COVID-19 patients was ineffective and may even be harmful. These patients received intravenous infusion of high doses of vitamin C, about 100 times more than commercially available vitamin C supplements. When questions were raised about its effectiveness, the research team abruptly halted clinical trials on vitamin C.
More than 2,500 patients from 20 countries participated in the vitamin C clinical trial, which integrated a specific clinical trial (REMAP-CAP) and another clinical trial (LOVIT-COVID). All hospitalized COVID-19 patients were included here, regardless of the severity of symptoms. It is the world’s largest in this field. The research team especially cautioned, “Clinicians should not use intravenous vitamin C to treat COVID-19 patients.”
“This will be of great help to medical experts around the world in improving the treatment of severe COVID-19 patients,” said Professor Anthony Gordon (surgery oncology), Imperial College London, lead author of the specific clinical trial (REMAP-CAP) study.
A specific clinical trial (REMAP-CAP) investigated treatments for patients hospitalized with COVID-19 since March 2020. 290 American patients participated in a vitamin C study at the University of Pittsburgh Medical Center (UPMC), Ohio State University Medical Center, and Oregon Health and Science University.
The results of this study (Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials) were published in the Journal of the American Medical Association (JAMA). The results of these two studies were introduced by the US health portal ‘Healthday’ and the UK’s Imperial College London website.
2023-10-27 04:37:30
#Corona #patients #vitamin #good #Stop
